Veru Shares Are Trading Higher Following Publication of Briefing Documents Ahead of the Nov. 9 FDA Adcom Meeting for Its COVID-19 Treatment Candidate.
Veru Shares Are Trading Higher Following Publication of Briefing Documents Ahead of the Nov. 9 FDA Adcom Meeting for Its COVID-19 Treatment Candidate.
在11月9日FDA Adcom会议之前发布简报文件后，Veru的股价上涨，VERU的候选新冠肺炎治疗方案。
Veru shares are trading higher following publication of briefing documents ahead of the Nov. 9 FDA Adcom meeting for its COVID-19 treatment candidate.
在11月9日FDA为其新冠肺炎候选药物举行的Adcom会议之前，Veru的股价在简报文件公布后走高。